Cialis FAERS Safety Signals: What the FDA's Adverse Event Data Actually Shows

How FAERS Works and Why It Matters for Tadalafil

The FDA Adverse Event Reporting System (FAERS) is a pharmacovigilance database that collects voluntary reports from patients, healthcare providers, and mandatory reports from manufacturers. The system does not prove causation. What it does do is generate quantitative signals that regulators investigate further, sometimes triggering label changes, Risk Evaluation and Mitigation Strategies (REMS), or market withdrawal.

For tadalafil specifically, FAERS has been the primary mechanism by which several now-labeled warnings were first detected. Understanding the database's structure helps clinicians interpret reports correctly rather than dismissing them wholesale or over-weighting individual cases.

How Signals Are Generated

The FDA uses Empirical Bayes Geometric Mean (EBGM) scoring and Proportional Reporting Ratios (PRR) to identify drug-event combinations that appear more frequently than expected by chance across the entire database. A PRR above 2.0 combined with at least three reports and a Chi-squared statistic above 4.0 generally meets the threshold for a signal worth investigating, per the FDA's standard methodology [1].

Tadalafil entered FAERS as a new molecular entity in late 2003. Within two years, the visual disturbance cluster containing NAION reports had accumulated enough statistical weight to prompt regulatory action.

Limitations Clinicians Must Know

FAERS carries well-documented limitations. Under-reporting is the dominant one. The FDA estimates that fewer than 10% of serious adverse events are ever reported spontaneously [2]. Reports also lack denominators, meaning the rate of an event per million prescriptions cannot be calculated directly from FAERS alone. The FDA's Sentinel System, a separate active-surveillance network drawing on insurance claims and electronic health records covering more than 330 million individuals, supplements FAERS for rate estimation [3].

Tadalafil FDA Approval History and Label Evolution

Tadalafil received its first FDA approval on November 21, 2003, for erectile dysfunction at doses of 10 mg and 20 mg taken as needed. Eli Lilly's New Drug Application was reviewed under standard review timeline. Brock et al. Published key Phase III data in the Journal of Urology in 2002, showing statistically significant improvements on the International Index of Erectile Function (IIEF) at both dose levels versus placebo (P<0.001) [4].

The label has been revised multiple times since initial approval. Each revision tells a story about what post-market surveillance found.

2005: Visual Disturbance Warning Added

Post-market case reports of non-arteritic ischemic optic neuropathy (NAION) associated with PDE5 inhibitor use prompted the FDA to require a labeling update across the class. The Cialis label was updated to include a warning that patients who experience sudden loss or decrease in vision should stop the drug and seek immediate evaluation. The FDA specifically noted that many NAION cases involved individuals with underlying anatomic or vascular risk factors, though a direct causal link was not definitively established [5].

2007: Sudden Hearing Loss Warning Added

In July 2007, the FDA issued a safety communication requiring all PDE5 inhibitor manufacturers to add a warning about sudden hearing loss. FAERS had accumulated spontaneous reports of sudden decrease or loss of hearing, sometimes accompanied by tinnitus and dizziness, following tadalafil use. The current Prescribing Information states: "Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing" [6].

2008 to 2012: BPH and Combination BPH/ED Approvals

The 5 mg once-daily dose for benign prostatic hyperplasia received approval in October 2009, and the indication was extended to cover BPH with comorbid ED as well. This broadened the patient population significantly, particularly among older men with cardiovascular comorbidities, which introduced a different risk profile into post-market surveillance data.

2018: Generic Entry and Surveillance Expansion

When tadalafil generics entered the U.S. Market in September 2018 following patent expiration, the pool of FAERS reporters expanded substantially. More prescriptions generate more reports. Clinicians reviewing raw FAERS counts for tadalafil after 2018 should account for the volume increase attributable to generic uptake rather than assuming a new safety signal.

The Major FAERS Safety Signals for Tadalafil

This section reviews each established or investigated signal by category, with the current label status and what post-market evidence shows.

Cardiovascular Signals

Hypotension and Nitrate Interaction

Tadalafil's mechanism, inhibition of phosphodiesterase type 5, potentiates the vasodilatory effect of nitric oxide. Concurrent use with organic nitrates produces additive and potentially severe hypotension. This interaction was identified in pre-approval pharmacodynamic studies and is listed as an absolute contraindication in Section 4 of the Prescribing Information [6].

FAERS continues to receive reports of hypotensive episodes in men who combined tadalafil with nitrates, including recreational amyl nitrite ("poppers"). The FDA has not changed the contraindication category. These reports serve primarily as a signal of real-world non-compliance with existing label guidance rather than a new pharmacological finding.

Alpha-Blocker Interaction

The combination of tadalafil with alpha-adrenergic blockers (used for hypertension or BPH) can produce symptomatic hypotension. FAERS reports cluster around doxazosin co-administration specifically. The label includes a dose-titration caution: patients on stable alpha-blocker therapy may initiate tadalafil at 5 mg, and patients already on tadalafil should begin alpha-blocker therapy at the lowest dose [6].

Myocardial Infarction Reports in FAERS

FAERS contains MI reports for tadalafil, but this signal requires careful interpretation. Men with erectile dysfunction carry a substantially elevated baseline cardiovascular risk independent of any drug they take. A 2005 analysis published in the Journal of the American College of Cardiology established that ED is an independent predictor of coronary artery disease events [7]. Confounding by indication is the dominant concern in interpreting cardiac FAERS reports for this drug class.

The Princeton Consensus (Third Princeton Consensus Conference, 2012) provides a risk stratification framework for prescribing PDE5 inhibitors to men with cardiovascular disease, categorizing patients as low, intermediate, or high risk [8]. Tadalafil is generally considered safe in low-risk patients without nitrate use.

Ophthalmologic Signals

Non-Arteritic Ischemic Optic Neuropathy (NAION)

NAION is a sudden loss of blood supply to the optic nerve. The estimated incidence of NAION in the general male population over 50 is approximately 2.5 to 11.8 per 100,000 person-years [9]. Case reports linking PDE5 inhibitors to NAION began accumulating in FAERS in 2004 and 2005.

The FDA reviewed these cases and concluded that a subset of patients may have had underlying structural risk factors (small cup-to-disc ratio, a condition sometimes called "disc at risk") that predisposed them to NAION. The label advises clinicians to consider whether the cardiovascular and anatomical risk profile warrants prescribing in patients who have already experienced NAION in one eye [6].

Prospective data have not definitively confirmed a causal relationship. A 2006 case-crossover study published in Ophthalmology found a statistically elevated odds ratio for PDE5 inhibitor use in the period preceding NAION onset [9], but absolute numbers remained small and confounding by shared vascular risk factors was acknowledged.

Other Visual Adverse Events

Blurred vision, color vision changes (particularly blue-green hue perception), and increased light sensitivity appear in FAERS tadalafil reports, although less frequently than with sildenafil. These effects are attributed to low-level PDE6 cross-inhibition in retinal photoreceptors. Tadalafil's selectivity ratio for PDE5 over PDE6 is approximately 700-fold, compared with sildenafil's approximately 10-fold ratio, which is consistent with tadalafil's lower rate of visual color disturbance in clinical trial data [10].

Auditory Signals

Sudden Sensorineural Hearing Loss

After the 2007 label update, FAERS continued to accumulate sudden hearing loss reports for tadalafil. The biological plausibility is supported by the presence of PDE5 in cochlear vasculature; vascular compromise in the stria vascularis may underlie the signal. Cases typically involve unilateral sudden hearing loss, often accompanied by tinnitus, and onset within 24 to 48 hours of drug ingestion.

A 2010 systematic review covering case reports and FAERS data identified 29 cases of sudden hearing loss associated with PDE5 inhibitors across all drugs in the class; tadalafil accounted for a minority of total cases, likely reflecting sildenafil's larger market share at that time [11]. The current label tells patients to stop taking tadalafil and call a doctor if they notice a sudden decrease or loss of hearing.

Priapism

Priapism (erection lasting more than four hours) is listed as a post-marketing adverse reaction requiring immediate medical attention. The mechanism involves prolonged smooth muscle relaxation in the corpora cavernosa. FAERS contains priapism reports for tadalafil, and the long half-life of tadalafil (17.5 hours, the longest in its class) is mechanistically relevant since drug exposure persists considerably longer than with shorter-acting PDE5 inhibitors [6].

Sickle cell anemia, multiple myeloma, and leukemia are identified in the label as conditions that predispose patients to priapism and warrant additional caution when considering tadalafil.

Drug-Drug Interaction Signals in FAERS

CYP3A4 Inhibitors

Tadalafil is metabolized primarily by CYP3A4. Strong inhibitors such as ketoconazole and ritonavir substantially increase tadalafil plasma concentrations. FAERS reports of adverse events in HIV-positive men on ritonavir-based regimens who were also prescribed tadalafil informed the current dosing cap: a maximum of 10 mg every 72 hours when co-administered with a potent CYP3A4 inhibitor [6].

Alcohol

FAERS contains reports of symptomatic hypotension in men who consumed substantial amounts of alcohol alongside tadalafil. The label states that substantial alcohol consumption (5 or more units) in combination with tadalafil may increase the risk of hypotension, orthostatic symptoms, and reflex tachycardia [6].

How FDA Sentinel Complements FAERS for Tadalafil Surveillance

FAERS is a passive, voluntary system. The FDA launched the Sentinel System in 2008 and it reached full operational status around 2016, drawing on longitudinal claims data and electronic health records from participating health plans, academic medical centers, and pharmacy chains [3].

For tadalafil, Sentinel surveillance has been used to examine whether observational co-prescription rates of tadalafil with contraindicated nitrates match what FAERS reporting would suggest. Active surveillance through Sentinel is better suited to rate estimation, because it has defined denominators.

The HealthRX clinical team uses a three-tier signal classification when reviewing FAERS tadalafil data for patient counseling:

Tier 1 (Label-codified, high confidence): Nitrate interaction hypotension, NAION, sudden hearing loss, priapism, alpha-blocker hypotension, CYP3A4 interaction.

Tier 2 (Signal under active review, low-to-moderate confidence): Melanoma association (under investigation since a 2014 observational study; not confirmed or label-updated as of this writing) [12].

Tier 3 (Case reports only, no signal threshold met): Peyronie's disease exacerbation, peripheral neuropathy, and isolated cases of hepatic enzyme elevation.

This framework is not a substitute for reading the full current Prescribing Information, which should always be consulted before prescribing.

Reading the Current Tadalafil Prescribing Information

The FDA-approved Prescribing Information (PI) for Cialis is accessible through Drugs@FDA and through accessdata.fda.gov. The document is organized in the standard 2006 Physician Labeling Rule format with numbered sections. Key sections for safety signal awareness are:

Section 4: Contraindications

The PI lists organic nitrates in any form as an absolute contraindication. Guanylate cyclase stimulators (specifically riociguat) are also contraindicated due to the risk of additive hypotension [6]. Clinicians prescribing tadalafil for BPH in men who may have been prescribed nitrates by a cardiologist should verify the full medication list before initiating therapy.

Section 5: Warnings and Precautions

This section covers cardiovascular effects, NAION, sudden hearing loss, priapism, and effects on bleeding (tadalafil potentiates the anticoagulant effect of warfarin at supratherapeutic concentrations in some models, though this interaction is listed as a precaution rather than a contraindication).

Section 6: Adverse Reactions

Section 6.1 (clinical trials experience) reports adverse reactions occurring in at least 2% of patients and more frequently than placebo. Headache was the most common adverse reaction in Phase III trials, occurring in 11% to 15% of patients on 10 mg to 20 mg doses versus 5% to 6% on placebo. Dyspepsia, back pain, myalgia, nasal congestion, and flushing round out the most frequent complaints [6].

Back pain and myalgia are more specific to tadalafil compared with other PDE5 inhibitors. This is attributed to PDE11A inhibition. PDE11A is expressed in skeletal muscle, and tadalafil has meaningful activity at PDE11A in contrast to its class peers [10].

Section 6.2: Post-Marketing Experience

Section 6.2 lists adverse reactions identified after approval that were not observed at sufficient frequency in clinical trials to appear in Section 6.1. This list currently includes NAION, sudden hearing loss, priapism, hypersensitivity reactions (including Stevens-Johnson Syndrome, listed as a rare report), and seizures [6].

What Clinicians Should Document When Suspecting a Tadalafil Adverse Event

If a patient presents with a potential tadalafil-associated adverse event, clinicians can submit a MedWatch report directly to the FDA at fda.gov/safety/medwatch. The form captures: suspected drug name and dose; event description; dates of onset and drug use; concomitant medications; and patient demographics.

Reporting takes approximately 15 to 30 minutes. The value is cumulative: a single report may not reach signal threshold, but a cluster of similar reports from multiple providers can trigger a formal FDA review. Tadalafil's 2007 hearing-loss label update was the direct result of enough spontaneous reports accumulating to reach EBGM signal threshold.

Patients can also report directly via the MedWatch consumer form. The FDA's OpenFDA API makes aggregate de-identified FAERS data publicly queryable at api.fda.gov/drug/event.json, allowing pharmacists and researchers to run real-time queries by drug name and event term [1].

Melanoma Signal: The Unsettled Question

A 2014 cohort study using data from the Health Professionals Follow-Up Study (N=25,848) reported a hazard ratio of 1.84 (95% CI 1.04 to 3.22) for melanoma among men who had ever used sildenafil, compared with non-users [12]. Tadalafil was not the primary drug studied, but because the proposed mechanism involved PDE5's role in melanocyte signaling, regulatory scrutiny extended to the entire drug class.

The FDA reviewed this signal and concluded that the available evidence was insufficient to establish causation or to require a label change as of the most recent published review. Subsequent studies have produced inconsistent results. A 2020 meta-analysis covering seven observational studies found no statistically significant pooled association between PDE5 inhibitor use and melanoma risk overall (pooled RR 1.12, 95% CI 0.95 to 1.32, P<0.05 threshold not met) [13].

This remains an area where clinicians are advised to maintain awareness. Dermatological screening in long-term tadalafil users is not currently recommended by any major guideline, but the signal has not been conclusively dismissed.

Tadalafil in Special Populations: What FAERS and Label Data Suggest

Older Adults

Men over 65 represented approximately 22% of tadalafil Phase III trial participants. Plasma concentrations of tadalafil in men over 65 were approximately 25% higher than in men aged 19 to 45 in pharmacokinetic studies. The label does not require mandatory dose reduction for age alone, but recommends starting at 5 mg as needed given this PK difference [6].

FAERS case reports suggest falls and syncope are more frequently reported in older men on tadalafil, consistent with the drug's blood-pressure-lowering properties interacting with age-related orthostatic vulnerability.

Hepatic Impairment

In Child-Pugh Class A or B hepatic impairment, the recommended maximum dose is 10 mg. Tadalafil has not been studied in Child-Pugh Class C patients, and the label states the drug is not recommended in that population [6].

Renal Impairment

For patients with creatinine clearance between 31 and 50 mL/min, the starting dose is 5 mg once daily and the maximum is 10 mg every 48 hours. For creatinine clearance below 30 mL/min or end-stage renal disease on dialysis, the maximum is 5 mg every 72 hours [6].